Article
Oncology
L. Paz-Ares, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, M. J. Hochmair, M. Ozguroglu, J. H. Ji, M. C. Garassino, O. Voitko, A. Poltoratskiy, E. Musso, L. Havel, I Bondarenko, G. Losonczy, N. Conev, H. Mann, T. B. Dalvi, H. Jiang, J. W. Goldman
Summary: In extensive-stage small-cell lung cancer (ES-SCLC), durvalumab plus EP continues to improve overall survival (OS), while durvalumab plus tremelimumab plus EP shows numerical improvement but does not reach statistical significance.
Article
Oncology
Tetsuhiko Asao, Satoshi Watanabe, Takahiro Tanaka, Satoshi Morita, Kunihiko Kobayashi
Summary: This study aims to assess the safety and efficacy of carboplatin and etoposide plus durvalumab in patients with ES-SCLC and a poor PS.
Article
Oncology
Katsuyuki Hotta, Makoto Nishio, Haruhiro Saito, Isamu Okamoto, Yasuharu Nakahara, Hidetoshi Hayashi, Manabu Hayama, Peter Laud, Haiyi Jiang, Luis Paz-Ares, Koichi Azuma
Summary: The first-line treatment of durvalumab plus EP demonstrated efficacy and good tolerability in Japanese patients with ES-SCLC. Despite the small sample size of the Japan subgroup, the results were generally consistent with the global study population.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Ozguroglu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, Gyorgy Losonczy, Nikolay V. Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares
Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.
Article
Immunology
Jun Ni, Xiaoyan Si, Hanping Wang, Xiaotong Zhang, Li Zhang
Summary: This study evaluates the preliminary efficacy and safety of camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer (ES-SCLC) patients. The results show that IP/IC plus camrelizumab group has a median PFS of 10.25 months, and the objective response rate is 89.6%.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Tiandong Kong, Lu Chen, Xiaoli Zhao, Fangfang Duan, Hanli Zhou, Lei Wang, Danna Liu
Summary: This study assessed the efficacy and safety of adding anlotinib to platinum-chemotherapy as first-line therapy for patients with extensive-stage small-cell lung cancer (ES-SCLC). The results showed that this combination therapy has anti-tumor activity and acceptable tolerability, providing a basis for future randomized controlled trials.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Oncology
Lijuan Li, Dan Yang, Yanmei Min, Anyan Liao, Jing Zhao, Leilei Jiang, Xin Dong, Wei Deng, Huiming Yu, Rong Yu, Jun Zhao, Anhui Shi
Summary: This study aimed to assess the safety and efficacy of chemoimmunotherapy combined with thoracic radiotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC). A total of 36 patients with ES-SCLC received this treatment modality at one hospital. The results showed that this treatment approach is safe and has good survival outcomes.
Article
Oncology
Jie Wang, Caicun Zhou, Wenxiu Yao, Qiming Wang, Xuhong Min, Gongyan Chen, Xingxiang Xu, Xingya Li, Fei Xu, Yong Fang, Runxiang Yang, Guohua Yu, Youling Gong, Jun Zhao, Yun Fan, Quan Liu, Lejie Cao, Yu Yao, Yunpeng Liu, Xiaoling Li, Jingxun Wu, Zhiyong He, Kaihua Lu, Liyan Jiang, Chengping Hu, Wenhua Zhao, Ben Zhang, Wei Shi, Xiaojing Zhang, Ying Cheng
Summary: The study evaluated the efficacy and safety of adebrelimab in combination with standard chemotherapy as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). The results showed that the addition of adebrelimab significantly improved overall survival and had an acceptable safety profile. Therefore, the combination of adebrelimab and chemotherapy may be a new treatment option for ES-SCLC patients.
Article
Oncology
Gangjun Chen, Tian Tian, Xingdong Cai
Summary: Small-cell lung cancer (SCLC) is a poorly differentiated neuroendocrine tumor with endocrine function. Chemotherapy and immune checkpoint inhibitors (ICIs) are the first-line treatment options, but ICIs can cause immune-related side effects in patients with chronic HBV infection. This case study presents a HBsAg-negative patient with increased HBsAb levels after receiving atezolizumab immunotherapy, indicating a potential solution for insufficient antibody production and therapeutic opportunity for HBV patients with cancers.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Martin Reck, Tony S. K. Mok, Aaron Mansfield, Richard De Boer, Gyorgy Losonczy, Shunichi Sugawara, Rafal Dziadziuszko, Maciej Krzakowski, Alexey Smolin, Maximilian Hochmair, Marina Chiara Garassino, Gilberto de Castro Junior, Helge Bischoff, Sivuonthanh Lam, Andres Cardona, Stefanie Morris, Stephen Liu
Summary: The IMpower133 study demonstrated that atezolizumab in combination with carboplatin and etoposide improved overall survival and progression-free survival in first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). Further analysis revealed that the benefits of atezolizumab maintenance therapy persisted after adjusting for baseline characteristics, and the safety profile was similar to the placebo group.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Health Care Sciences & Services
Dongchu Zhou, Xinrui Dong, Zhen Zhou, Qiao Liu
Summary: The affordable price range for adebrelimab/mg for Chinese patients with untreated ES-SCLC was estimated to be between $0.252 and $0.824, with variations observed across different subgroups. In the context of universal healthcare coverage, our study provides valuable evidence to inform the implementation of a value-based pricing strategy for cancer treatment.
RISK MANAGEMENT AND HEALTHCARE POLICY
(2023)
Article
Oncology
Davide Melisi, Do-Youn Oh, Antoine Hollebecque, Emiliano Calvo, Anna Varghese, Erkut Borazanci, Teresa Macarulla, Valeria Merz, Camilla Zecchetto, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Leena Gandhi, Shawn T. Estrem, Karim A. Benhadji, Mark C. Lanasa, Emin Avsar, Susan C. Guba, Rocio Garcia-Carbonero
Summary: The study assessed the safety, efficacy, and pharmacokinetics of the combination therapy of galunisertib and durvalumab in patients with recurrent/refractory metastatic pancreatic cancer. The results showed tolerability of the combination therapy, with limited clinical activity observed. Further studies in patients in earlier lines of treatment or with predictive biomarkers of TGF beta inhibition may be more suitable.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Yoshimasa Shiraishi, Takayuki Shimose, Yuko Tsuchiya-Kawano, Hidenobu Ishii, Haruko Daga, Kentaro Ito, Koichi Saruwatari, Isamu Okamoto
Summary: This study aims to evaluate the effects of ICI with PE combination therapy on ES-SCLC patients with brain metastases. By observing intracranial response rate and other indicators, the study hopes to provide a potential treatment option for these patients, avoiding or postponing radiation therapy or surgery for brain metastases.
CANCER MANAGEMENT AND RESEARCH
(2022)
Article
Oncology
Elisa Andrini, Giuseppe Lamberti, Francesca Mazzoni, Ferdinando Riccardi, Andrea Bonetti, Alessandro Follador, Fabrizio Artioli, Carlo Genova, Fausto Barbieri, Antonio Frassoldati, Matteo Brighenti, Ida Colantonio, Giulia Pasello, Corrado Ficorella, Saverio Cinieri, Marcello Tiseo, Francesco Gelsomino, Michele Tognetto, Karim Rihawi, Andrea Ardizzoni
Summary: Extended-stage small-cell lung cancer (ES-SCLC) is an aggressive subtype with poor prognosis. The combination of chemotherapy, antiangiogenic therapy, and immunotherapy may improve survival. The CeLEBrATE trial aims to assess the efficacy and safety of this combination treatment.
Article
Oncology
Yoo-Na Kim, Je-Gun Joung, Eunhyang Park, Jae-Weon Kim, Jung Bok Lee, Jinyeong Lim, Sunghoon Kim, Chel Hun Choi, Hee Seung Kim, Jongsuk Chung, Byoung-Gie Kim, Jung-Yun Lee
Summary: Choosing the right combination of drugs based on patient-specific biomarkers can improve treatment efficacy in ovarian cancer. However, the efficacy and safety of different combinations of PARP inhibitors have not been evaluated in ovarian cancer patients with HRR mutations. In this study, we compared two olaparib-based combinations in platinum-resistant ovarian cancer patients with HRR gene mutations and found similar response rates and manageable adverse events in both groups. We also identified biomarkers associated with treatment outcomes and proposed a comprehensive biomarker profiling approach to guide treatment selection. These findings have the potential to improve treatment outcomes in the PARP inhibitor era.
INTERNATIONAL JOURNAL OF CANCER
(2023)